Literature DB >> 15842117

A population-based analysis of pneumococcal disease mortality in California, 1989-1998.

Matthew D Redelings1, Frank Sorvillo, Paul Simon.   

Abstract

OBJECTIVES: Pneumococcal disease is an important cause of vaccine-preventable mortality. It is important to understand the burden and distribution of mortality so that prevention efforts can be targeted appropriately. This study evaluated pneumococcal disease mortality and its demographic correlates in California from 1989 to 1998.
METHODS: Deaths due to pneumococcal disease were identified from statewide vital records data using multiple cause-coded information. Denominator data were obtained from estimates from the California Department of Finance. Crude and age-adjusted mortality rates and 95% confidence intervals were calculated for each age, gender, and racial/ethnic group.
RESULTS: The age-adjusted pneumococcal disease mortality rate was 2.05 deaths per 100,000 population. Mortality was highest in elderly individuals (reaching 38.29 deaths per 100,000 population in individuals older than age 85). Age-adjusted mortality rates were elevated in the African American race/ethnicity group (2.96 deaths per 100,000 population) and males (2.67 deaths per 100,000 population). The majority of individuals who died of pneumococcal disease (78.9%) fell into at-risk groups indicated for vaccination. The majority of all pneumococcal deaths were caused by pneumococcal pneumonia. Mortality was seasonal, reaching a peak in the winter months. A decreasing trend in mortality was observed over the 10-year period examined.
CONCLUSIONS: Pneumococcal disease remains a significant cause of vaccine-preventable mortality in the California population. Greater efforts must be made to vaccinate at-risk individuals, especially those in demographic groups at highest risk of death.

Entities:  

Mesh:

Year:  2005        PMID: 15842117      PMCID: PMC1497698          DOI: 10.1177/003335490512000209

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  29 in total

1.  Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era.

Authors:  K A Robinson; W Baughman; G Rothrock; N L Barrett; M Pass; C Lexau; B Damaske; K Stefonek; B Barnes; J Patterson; E R Zell; A Schuchat; C G Whitney
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

2.  Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California.

Authors:  J P Nuorti; J C Butler; L Gelling; J L Kool; A L Reingold; D J Vugia
Journal:  Ann Intern Med       Date:  2000-02-01       Impact factor: 25.391

3.  Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team.

Authors:  J P Nuorti; J C Butler; M M Farley; L H Harrison; A McGeer; M S Kolczak; R F Breiman
Journal:  N Engl J Med       Date:  2000-03-09       Impact factor: 91.245

4.  Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients.

Authors:  R F Breiman; D W Keller; M A Phelan; D H Sniadack; D S Stephens; D Rimland; M M Farley; A Schuchat; A L Reingold
Journal:  Arch Intern Med       Date:  2000-09-25

5.  Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group.

Authors:  S Black; H Shinefield; B Fireman; E Lewis; P Ray; J R Hansen; L Elvin; K M Ensor; J Hackell; G Siber; F Malinoski; D Madore; I Chang; R Kohberger; W Watson; R Austrian; K Edwards
Journal:  Pediatr Infect Dis J       Date:  2000-03       Impact factor: 2.129

6.  Pneumococcal immunizations at flu clinics: the impact of community-wide outreach.

Authors:  D Shenson; J Quinley; D DiMartino; P Stumpf; M Caldwell; T Lee
Journal:  J Community Health       Date:  2001-06

7.  The clinical effectiveness of pneumococcal vaccine in the elderly.

Authors:  R V Sims; W C Steinmann; J H McConville; L R King; W C Zwick; J S Schwartz
Journal:  Ann Intern Med       Date:  1988-05       Impact factor: 25.391

8.  Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.

Authors:  C G Whitney; M M Farley; J Hadler; L H Harrison; C Lexau; A Reingold; L Lefkowitz; P R Cieslak; M Cetron; E R Zell; J H Jorgensen; A Schuchat
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

Review 9.  Pneumococcal disease in the elderly: what is preventing vaccine efficacy?

Authors:  J B Rubins; E N Janoff
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

10.  Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection.

Authors:  K L O'Brien; M I Walters; J Sellman; P Quinlisk; H Regnery; B Schwartz; S F Dowell
Journal:  Clin Infect Dis       Date:  2000-05-18       Impact factor: 9.079

View more
  4 in total

1.  Mortality reductions for older adults differ by race/ethnicity and gender since the introduction of adult and pediatric pneumococcal vaccines.

Authors:  Samir Soneji; Joshua Metlay
Journal:  Public Health Rep       Date:  2011 Mar-Apr       Impact factor: 2.792

Review 2.  Disease-Specific Health Disparities: A Targeted Review Focusing on Race and Ethnicity.

Authors:  Mark R Cullen; Adina R Lemeshow; Leo J Russo; David M Barnes; Yaa Ababio; Aida Habtezion
Journal:  Healthcare (Basel)       Date:  2022-03-23

Review 3.  Burden of pneumonia and meningitis caused by Streptococcus pneumoniae in China among children under 5 years of age: a systematic literature review.

Authors:  Ying Chen; Wei Deng; Song-Mei Wang; Qi-Mei Mo; Huan Jia; Qun Wang; Song-Guang Li; Xiang Li; Bao-Dong Yao; Cheng-Jun Liu; Yi-Qiang Zhan; Chen Ji; Anna Lena Lopez; Xuan-Yi Wang
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

4.  The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004.

Authors:  John D Mooney; Amanda Weir; Jim McMenamin; Lewis D Ritchie; Tatania V Macfarlane; Colin R Simpson; Syed Ahmed; Chris Robertson; Stuart C Clarke
Journal:  BMC Infect Dis       Date:  2008-04-23       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.